Geode Capital Management, LLC Blueprint Medicines Corp Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,371,127 shares of BPMC stock, worth $158 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,371,127

Previous 1,327,256 3.31%

Holding current value

$158 Million

Previous $122 Million 6.24%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$73.17 - $99.79 $3.21 Million - $4.38 Million	43,871 Added 3.31%	1,371,127 $130 Million
Q4 2023 Feb 13, 2024	BUY	$43.96 - $92.84 $2.67 Million - $5.64 Million	60,759 Added 4.8%	1,327,256 $122 Million
Q3 2023 Nov 13, 2023	BUY	$46.9 - $66.0 $2.12 Million - $2.99 Million	45,304 Added 3.71%	1,266,497 $63.6 Million
Q2 2023 Aug 11, 2023	BUY	$42.2 - $66.37 $2.47 Million - $3.89 Million	58,553 Added 5.04%	1,221,193 $77.2 Million
Q1 2023 May 15, 2023	BUY	$37.97 - $50.0 $1.83 Million - $2.42 Million	48,303 Added 4.33%	1,162,640 $52.3 Million

Q4 2022 Feb 13, 2023	BUY	$41.06 - $66.48 $1.6 Million - $2.6 Million	39,044 Added 3.63%	1,114,337 $48.8 Million
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $1.32 Million - $2.05 Million	26,344 Added 2.51%	1,075,293 $70.9 Million
Q2 2022 Aug 12, 2022	BUY	$45.23 - $70.15 $558,183 - $865,721	12,341 Added 1.19%	1,048,949 $53 Million
Q1 2022 May 13, 2022	BUY	$54.1 - $110.08 $361,225 - $735,004	6,677 Added 0.65%	1,036,608 $66.2 Million
Q4 2021 Feb 11, 2022	BUY	$94.25 - $115.99 $1.59 Million - $1.96 Million	16,881 Added 1.67%	1,029,931 $110 Million
Q3 2021 Nov 12, 2021	SELL	$80.98 - $109.47 $741,047 - $1 Million	-9,151 Reduced 0.9%	1,013,050 $104 Million
Q2 2021 Aug 13, 2021	BUY	$82.78 - $101.0 $4.61 Million - $5.63 Million	55,705 Added 5.76%	1,022,201 $89.9 Million
Q1 2021 May 12, 2021	BUY	$90.71 - $108.28 $9.12 Million - $10.9 Million	100,534 Added 11.61%	966,496 $94 Million
Q4 2020 Feb 12, 2021	BUY	$92.08 - $124.48 $4.17 Million - $5.63 Million	45,264 Added 5.52%	865,962 $97.1 Million
Q3 2020 Nov 13, 2020	SELL	$66.45 - $92.7 $173,168 - $241,576	-2,606 Reduced 0.32%	820,698 $76.1 Million
Q2 2020 Aug 13, 2020	BUY	$57.09 - $79.27 $1.7 Million - $2.35 Million	29,695 Added 3.74%	823,304 $64.2 Million
Q1 2020 May 14, 2020	BUY	$48.11 - $82.22 $4.92 Million - $8.41 Million	102,291 Added 14.8%	793,609 $46.4 Million
Q4 2019 Feb 13, 2020	BUY	$66.73 - $82.59 $1.98 Million - $2.45 Million	29,612 Added 4.48%	691,318 $55.4 Million
Q3 2019 Nov 12, 2019	BUY	$72.9 - $101.41 $610,829 - $849,714	8,379 Added 1.28%	661,706 $48.6 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $8.56 Million - $11.4 Million	116,404 Added 21.68%	653,327 $61.6 Million
Q1 2019 May 14, 2019	BUY	$48.7 - $86.6 $2.16 Million - $3.83 Million	44,261 Added 8.98%	536,923 $43 Million
Q4 2018 Feb 13, 2019	BUY	$45.57 - $74.26 $1.39 Million - $2.26 Million	30,499 Added 6.6%	492,662 $26.6 Million
Q3 2018 Nov 13, 2018	BUY	$58.91 - $78.32 $3.2 Million - $4.26 Million	54,352 Added 13.33%	462,163 $36.1 Million
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $1.92 Million - $3.18 Million	31,415 Added 8.35%	407,811 $25.9 Million
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $513,326 - $721,164	7,005 Added 1.9%	376,396 $34.5 Million
Q4 2017 Feb 13, 2018	BUY	$62.91 - $88.32 $2.23 Million - $3.13 Million	35,455 Added 10.62%	369,391 $27.9 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $756,050 - $1.24 Million	17,844 Added 5.65%	333,936 $23.3 Million
Q2 2017 Aug 14, 2017	BUY	N/A	316,092	316,092 $16 Million

Others Institutions Holding BPMC

# of Institutions

313

Shares Held

60.6M

Call Options Held

634K

Put Options Held

691K

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.88B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Blueprint Medicines Corp Transaction History